Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics (NQ: CORT )

21.23 USD +0.31 (+1.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 638,657
Open 21.05
Bid (Size) 21.22 (24)
Ask (Size) 21.23 (7)
Prev. Close 20.92
Today's Range 20.83 - 21.44
52wk Range 12.20 - 31.18
Shares Outstanding 116,630,692
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results
From GlobeNewswire News Releases
Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatit
From GlobeNewswire News Releases

Performance

YTD
-18.63%
-18.63%
1 Month
-7.45%
-7.45%
3 Month
-24.42%
-24.42%
6 Month
+17.29%
+17.29%
1 Year
+51.00%
+51.00%

More News

Read More
Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer
From GlobeNewswire News Releases
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From GlobeNewswire News Releases
Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess
From GlobeNewswire News Releases
Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer
From GlobeNewswire News Releases
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results
From GlobeNewswire News Releases
Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients
Tags General News NASH
From Benzinga
Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript
Tags Market News CORT
From Motley Fool
How The Pieces Add Up: PJP Headed For $90
Tags ETFs
From ETF Channel
Why Corcept Therapeutics, Acasti Pharma And More Are Moving Today
Tags Small Cap Benzinga TMDX
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.